Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BX004
- Development stage
- Phase 2
- Lead developer
- BiomX, Inc.
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Inhalation
01
Overview
BX004 is BiomX's investigational, nebulized fixed three-bacteriophage cocktail for chronic pulmonary *Pseudomonas aeruginosa* infection in people with cystic fibrosis. The phages are intended to selectively infect, replicate within, and lyse susceptible *P. aeruginosa* cells, thereby lowering bacterial burden in the airways. BX004-A was evaluated in a Phase 1b/2a study, and BiomX subsequently initiated a Phase 2b study; however, BiomX discontinued the Phase 2b cystic-fibrosis trial on December 8, 2025, following Data Monitoring Committee feedback and an internal review of unexpectedly high adverse-event rates. ([nature.com](https://www.nature.com/articles/s41467-025-60598-4))
02
Targets
P. aeruginosa LPS (Pseudomonas aeruginosa lipopolysaccharide)BtuB (Vitamin B12 transporter BtuB)OprM (Outer membrane protein OprM)P. aeruginosa (Pseudomonas aeruginosa)
Beyond the preview
Go deeper on BX004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BX004.